Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 225Lymphoma, Large B-Cell, Diffuse 160Small Cell Lung Carcinoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Lymphoma, Non-Hodgkin 139Leukemia 135Leukemia, Myeloid, Acute 117Hodgkin Disease 106Lung Neoplasms 99Burkitt Lymphoma 99Lymphoma, Follicular 85Lymphoma, Mantle-Cell 76Lymphoma, Large-Cell, Immunoblastic 68Carcinoma, Non-Small-Cell Lung 61Neuroblastoma 60Leukemia, Lymphocytic, Chronic, B-Cell 56Recurrence 53Multiple Myeloma 52Lymphoma, B-Cell, Marginal Zone 43Congenital Abnormalities 43Sarcoma 39Central Nervous System Neoplasms 39Myelodysplastic Syndromes 35Brain Neoplasms 34Ovarian Neoplasms 32Leukemia, Myelomonocytic, Acute 32Lymphoma, B-Cell 31Leukemia, Monocytic, Acute 31Leukemia, Erythroblastic, Acute 31Testicular Neoplasms 30

Interventions

Carboplatin 15Pemetrexed 7Paclitaxel 7pembrolizumab 4durvalumab 4osimertinib 3entinostat 3Gemcitabine 3Erlotinib Hydrochloride 3Cisplatin 3selpercatinib 2pralsetinib 2efatutazone 2atezolizumab 2Radiosurgery 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1napabucasin 1ficlatuzumab 1exemestane 1cobimetinib 1ceralasertib 1cemiplimab 1camrelizumab 1alectinib 1aflutinib 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Neoplasms × Etoposide × Clear all
NCT06177925 2023-12-20

A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Nanfang Hospital, Southern Medical University

Phase 2 Recruiting
62 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡